Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Processa Pharmaceuticals, Inc. Director's Dealing 2025

Feb 18, 2025

35172_dirs_2025-02-18_446c4380-16d3-4d5e-a820-9ebb1424ac8b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2025-01-27

Reporting Person: Yorke Justin W (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-01-29 Warrants $0.65 A 12400 Acquired 2030-01-29 Common Stock (12400) Indirect
2025-01-29 Warrants $0.65 A 6200 Acquired 2030-01-29 Common Stock (6200) Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 3737 Direct
Common Stock 12400 Indirect
Common Stock 31232 Indirect